Seven Grand Managers’s Stoke Therapeutics STOK Stock Holding History

Seven Grand Managers’s Portfolio STOK Stock Details STOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-30,000	Closed	-$405K	–	67
2024 Q1	$405K	Buy	+30,000	New	+$182K	0.2%	43

Other funds holding STOK

Skorpios Trust Limassol, Cyprus $53.2M AUM 90.96% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Seven Grand Managers's STOK Position: Q2 2024 in Review

Seven Grand Managers sold out of Stoke Therapeutics (STOK) in Q2 2024, closing a stake of 30,000 shares — an estimated $405K sold.

Seven Grand Managers first reported a position in STOK in Q1 2024 and held it in 1 quarter. The position peaked at $405K in Q1 2024. 114 funds tracked by Wall St. Rank hold STOK as of Q2 2024.

Seven Grand Managers reported no remaining Stoke Therapeutics position as of Q2 2024 after selling out during the quarter.
Seven Grand Managers sold 30,000 Stoke Therapeutics shares in Q2 2024, an estimated $405K.
Seven Grand Managers first reported a position in Stoke Therapeutics in Q1 2024 and held it in 1 quarter.
Seven Grand Managers's Stoke Therapeutics position peaked at $405K in Q1 2024.
114 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2024.

Based on Seven Grand Managers's 13F filing for Q2 2024, filed 14 Aug 2024.